Bronchospasmolytic effects of salbutamol as powder inhalation in patients with reversible bronchial obstruction.
In a double-blind double-dummy crossover study, the effects of salbutamol dry powder inhaled from Salbutamol cyclocaps Pharbita 0.4 mg with the Pharbita inhaler and from a reference product were compared. On the first trial day, a single dose of one of the two preparations was administered, and 2 days later a single dose of the another preparation was administered, in random order. The effects on lung function (FEV1) were monitored from 15 to 360 min after administration. For both products the increase in FEV1 with reference to baseline values was statistically highly significant. There was no significant difference between the products.